Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Poherdy. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Pertuzumab-Dpzb (sold as Poherdy), first approved Nov 13, 2025, with 0 new uses approved and 0 published complete response letters.
First approved in Japan 149 months before the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
PerjetaA drug with a new indication and a new dosage for the treatment of unresectable advanced or recurrent HER2-positive colon or rectal cancer that has… · Chugai Pharmaceutical Co., Ltd. · Mar 28, 2022 · Review report
PerjetaA drug with a new indication for the treatment of HER2-positive breast cancer. · Chugai Pharmaceutical Co., Ltd. · Oct 10, 2018
Perjeta, new ingredientA drug with a new active ingredient indicated for the treatment of unresectable or recurrent HER2- positive breast cancer. · Chugai Pharmaceutical Co., Ltd. · Jun 28, 2013 · Review report
Clinical Trials
4 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
